2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

1944 A phase 1, open-label, multicenter study of ltz-301, a first-in-class myeloid cell engager, in patients with relapsed/refractory B-cell non-Hodgkin lymphomas (LTZ-301-001, NCT07121946)

Michael Byrne, DO, Ajay Gopal, MD2, Dilan Anil Patel, MD3, Pallawi Torka, MD4, Sherry Unabia5, Danielle Talbot6, Amy-Jo Casbon7, Stefan Knackmuss8, Robert Li9, L. Elizabeth Elizabeth Budde, MD PhD10
1 Greco-Hainsworth Tennessee Oncology Centers for Research, Nashville, Tennessee, United States
2 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
3 Siteman Cancer Center, Washington University in St Louis School of Medicine, St Louis, Missouri, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 LTZ Therapeutics, Redwood City, California, United States
6 LTZ Therapeutics, Redwood City, California, United States
7 LTZ Therapeutics, Redwood City, California, United States
8 LTZ Therapeutics, Redwood City, California, United States
9 LTZ Therapeutics, Redwood City, California, United States
10 City of Hope National Medical Center, Duarte, California, United States

Background and Significance

Non-Hodgkin lymphoma (NHL) is among the most common cancers in the United States (US) and Europe with more than 89,000 and 93,000 new cases diagnosed every year, respectively (Ferlay 2015). Although advances in therapy have improved patient outcomes, many individuals ultimately develop relapsed or refractory (R/R) disease, highlighting the continued need for novel treatment approaches. Current immunotherapies targeting CD19 and CD20 have demonstrated significant clinical benefit; however, their efficacy may be limited by mechanisms of resistance, including antigen loss, as well as treatment-associated toxicities. T-cell engagers have demonstrated substantial clinical activity in R/R B-cell malignancies but remain associated with immune-mediated toxicities and mechanisms of resistance including antigen loss and T cell exhaustion. Myeloid cells represent abundant innate immune effectors within the lymphoma tumor microenvironment and treatment induced phagocytosis provides an alternative therapeutic approach.

LTZ-301 is a first-in-class anti-CD79b bispecific myeloid cell engager (U-MCETM)designed to induce phagocytosis of CD79b-expressing tumor cells by tumor-associated macrophages, regardless of subtype.

Preclinically, LTZ-301 demonstrated potent anti-tumor killing by eliminating both wild-type and truncated CD79b expressing lymphoma cell lines via FcyR independent phagocytosis. Additionally, LTZ-301 led to robust phagocytosis of both major molecular subtypes of diffuse large B-cell lymphoma cell lines (Activated B-Cell (ABC) and Germinal Center B-Cell (GCB)). Moreover, there was no evidence of cytokine release syndrome during in vitro human PBMC assays and only mild, transient release of IL-6 was observed in our in vivo non-human primate study which demonstrated rapid peripheral B-cell depletion. These features differentiate LTZ-301 from other immune cell engagers and other CD79b-targeted approaches.

LTZ-301-001 is a phase 1, open-label, multicenter, US-centric study evaluating the safety and tolerability of LTZ-301 in adults with R/R B-cell malignancies (NCT07121946)

Study Design and Method

Eligible participants are >18 years with confirmed diffuse large B-cell lymphoma, transformed follicular lymphoma, mantle cell lymphoma, or marginal zone lymphoma, all of which is R/R to at least 2 prior systemic treatment regimens. Other inclusion criteria include Eastern Cooperative Oncology Group performance status of 0 or 1 and adequate bone marrow, cardiac, pulmonary, renal, and hepatic function. Exclusion criteria include known double/triple hit lymphoma (MYC, and BCL-2 or BCL-6 translocations), CLL, or Richters transformation, eligibility for ASCT, prior solid organ transplant, prior allogeneic stem cell transplant, severe allergic or anaphylactic reactions to mAb, involvement of the central nervous system, confirmed progressive multifocal leukoencephalopathy, active autoimmune disease, and uncontrolled active infections including EBV, HBV, HCV, and HIV.

Approximately 40 participants will be enrolled across two parts of the study. In Part  I, participants will be enrolled in an accelerated dose-escalation phase followed by a 3+3 dose-escalation design with the option to expand certain dose levels into backfill cohorts. In Part II, participants will be enrolled in disease specific expansion cohorts. LTZ-301 will be administered weekly for the first cycle (28 days each). Subjects will then receive treatment for 4 further cycles with infusions every 2 weeks. Assessments will include positron emission tomography-computed tomography (PET-CT) at baseline, week 8, and week 20 of the study. Subjects exhibiting acceptable safety and evidence of clinical benefit at 20 weeks may continue to receive LTZ-301 at a Q3W cadence until disease progression or unacceptable toxicity with PET-CT imaging at three-month intervals. Safety will be evaluated based on incidence of AEs, SAEs, and DLTs according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

The primary objectives are to evaluate safety, tolerability, and determine the recommended Phase 2 dose. Secondary objectives include characterization of pharmacokinetics, immunogenicity, and preliminary antitumor activity. Exploratory objectives include pharmacodynamic assessments, exposure/PD/response analyses, and evaluation of blood- and tissue-based biomarkers.

Enrollment is ongoing in the dose-escalation phase. 

Michael Byrne, DO: Sun Pharmaceuticals - Consultancy (Includes expert testimony)